Premium
Impact of IL28B polymorphisms on 24‐week telaprevir‐based combination therapy for A sian chronic hepatitis C patients with hepatitis C virus genotype 1b
Author(s) -
Tsubota Akihito,
Shimada Noritomo,
Atsukawa Masanori,
Abe Hiroshi,
Kato Keizo,
Ika Makiko,
Matsudaira Hiroshi,
Nagatsuma Keisuke,
Matsuura Tomokazu,
Aizawa Yoshio
Publication year - 2014
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.12402
Subject(s) - telaprevir , medicine , genotype , gastroenterology , combination therapy , pegylated interferon , ribavirin , hepatitis c virus , single nucleotide polymorphism , cirrhosis , virology , immunology , virus , gene , biology , biochemistry
Background and Aim The aim of this study was to clarify which or how factors could influence the probability of sustained virological response ( SVR ) in 24‐week telaprevir‐based triple combination therapy for E ast A sian chronic hepatitis C patients infected with hepatitis C virus genotype 1b. Methods Of 140 patients who were enrolled in this study, 137 received 12‐week telaprevir combined with 24‐week pegylated interferon alpha‐2b plus ribavirin and were subjected to the analysis. Factors associated with SVR were analyzed by multiple logistic regression analysis. Results Of the 137 patients, 112 (82%) achieved SVR . Of 87 patients with IL28B single nucleotide polymorphism rs8099917 genotype TT , 84 (97%) achieved SVR . By contrast, 28 of 50 (56%) patients with the genotype TG / GG had SVR ( P = 3.29 × 10 −9 ). Fifty‐three of 60 (88%) naïve patients and 50 of 54 (93%) prior relapsers achieved SVR . Nine of 13 (69%) prior partial responders and none of 10 (0%) prior null responders achieved SVR . Multivariable analysis identified four independent factors that were significantly associated with SVR : IL28B SNP rs8099917 genotype ( P = 6.90 × 10 −5 ), pre‐existence of cirrhosis ( P = 3.99 × 10 −3 ), prior treatment response ( P = 0.0126), and rapid virological response ( P = 0.0239). Conclusions The IL28B single nucleotide polymorphism still remained informative as a predictor of SVR to 24‐week telaprevir‐based triple combination therapy for E ast A sian patients infected with hepatitis C virus genotype 1b.